ESCRS - FP18.08 - Ten Years Outcomes Of Eyecryl Phakic Posterior Chamber Intraocular Lenses: Safety And Efficacy In High Myopia Treatment

Ten Years Outcomes Of Eyecryl Phakic Posterior Chamber Intraocular Lenses: Safety And Efficacy In High Myopia Treatment

Published 2025 - 43rd Congress of the ESCRS

Reference: FP18.08 | Type: Free paper | DOI: 10.82333/q6jc-7j79

Authors: Patricia Ioschpe Gus* 1 , Rodrigo Pellegrini 2 , Larissa Ruela de Oliveira 3 , Eduardo Rott 3 , Carolina Parckert 3 , Leticia Paludo 4 , Diane Marinho 5

1Ophthalmology,Hospital de Clínicas de Porto Alegre,Porto Alegre,Brazil;Ophthalmology,Centro de Miopia & Ceratocone,Porto Alegre,Brazil, 2Hospital de Clínicas de Porto Alegre,Porto Alegre,Brazil, 3Medicine,Universidade Federal do Rio Grande do Sul,Porto Alegre,Brazil, 4Ophthalmology,Hospital de Clínicas de Porto Alegre,Porto Alegre,Brazil, 5Ophthalmology,Universidade Federal do Rio Grande do Sul,Porto Alegre,Brazil

Purpose

To evaluate the long-term efficacy and safety of Eyecryl Phakic posterior chamber intraocular lenses (IOLs) in the treatment of high myopia.

Setting

University of Health Sciences Beyoglu Eye Training and Research Hospital, Istanbul, Turkey

Methods

A retrospective analysis was conducted on highly myopic eyes implanted with Eyecryl Phakic (Biotech Vision Care, Ahmedabad, India) IOLs, with a minimum follow-up of ten years. Spherical equivalent (SE) of manifest refraction, uncorrected and corrected distance visual acuities (UDVA and CDVA, respectively), and endothelial cell density (ECD) were assessed preoperatively and at ten years postoperatively. The vault values ​​in the first and tenth years were noted. Complications were recorded. The safety index was defined as the ratio of postoperative CDVA to preoperative CDVA, and the efficacy index was defined as the ratio of postoperative UDVA to preoperative CDVA.

Results

The study included 34 eyes from 17 patients. Mean SE improved from −12.41±2.7 diopters (D) preoperatively to −0.95±1.1 D at ten years (p<0.001). Mean UDVA improved from 1.53±0.3 logMAR preoperatively to 0.29±0.4 logMAR postoperatively (p<0.001). The safety index was 1.54±0.7, and the efficacy index was 1.15±0.6. Mean endothelial cell loss at ten years was 7.11%, with no patient experiencing a ≥25% loss. No severe complications affecting CDVA were observed. Vault was 0.53±0.1 mm in the 1st year and 0.45±0.1 mm in the 10th year (p=0.001). Asymptomatic anterior subcapsular opacity was observed in one eye (2.9%), rhegmatogenous retinal detachment in another (2.9%), and early-stage age-related posterior subcapsular cataract in four eyes (11.7%).

Conclusions

Eyecryl Phakic posterior chamber IOLs demonstrate sustained efficacy and safety in the surgical correction of high myopia over a ten-year period, yielding significant improvements in visual acuity and refractive stability. The low incidence of complications, with no vision-threatening events directly attributable to the lens, supports their safety profile. However, given the progressive nature of endothelial changes, extended follow-up is essential to fully elucidate the long-term safety profile of these implants.